SightScore by Seonix Bio: First Polygenic Glaucoma Risk Test Now in the U.S.

SightScore harnesses the power of genetic testing to help ophthalmologists make decisions about disease risk.

Seonix Bio (Adelaide, Australia) has announced the U.S. launch of SightScore, the first commercially available polygenic risk score (PRS) testing service for primary open-angle glaucoma (POAG).¹

Already in use in Australia and New Zealand, SightScore uses a simple saliva sample to analyze millions of genetic variants, providing a personalized assessment of a patient’s glaucoma risk. 

For those already diagnosed, the test also predicts the likelihood of disease progression, equipping clinicians with critical insights for earlier intervention and more tailored treatment strategies.

The power of personalization in glaucoma

Dr. Inder Paul Singh, president of The Eye Centers of Racine & Kenosha, Ltd., called SightScore a “game changer” in glaucoma risk assessment. 

“By incorporating SightScore into our practice, we can more effectively prioritize patients for early screening, personalize their care and ensure we’re detecting glaucoma in its earliest, most treatable stages,” he said.

Nick Haan, CEO of Seonix Bio, emphasized the importance of this launch: “In the past, clinical genetic risk assessment for glaucoma has targeted a single gene or tens of genetic variants. As the first truly polygenic clinical genetic risk score for glaucoma on the market, using 7 million genetic variants, SightScore represents a major step forward in how we diagnose and manage this disease.”

Worldwide impact

Glaucoma affects nearly 80 million people worldwide², and conventional glaucoma risk assessments—relying on family history, age and standard eye exams—fall short in accurately predicting risk and enabling timely intervention. 

With SightScore, Seonix Bio aims to help clinicians identify high-risk individuals for earlier intervention and personalized management.

References

1. Business Wire. Seonix Bio Announces US Launch of SightScore, the First Commercially Available Clinical Polygenic Risk Score Testing Service for Glaucoma. Available at https://www.businesswire.com/news/home/20250220762988/en/Seonix-Bio-Announces-US-Launch-of-SightScore-the-First-Commercially-Available-Clinical-Polygenic-Risk-Score-Testing-Service-for-Glaucoma Accessed on February 21, 2025. 
2. Don’t Lose Sight of Glaucoma – Information for People at Risk. NIH Publication No. 12-3251 (revised 2012).